Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (April 2024)
19 slides from Cns Pharmaceuticals's investor presentation, Apr 15, 2024
Slide 1: Investor Presentation April 2024
INVESTOR PRESENTATION April 2024 www.CNSPharma.com NASDAQ: CNSP
Slide 2: Forward Looking Statements
NASDAQ: CNSP This presentation incorporates information from materials filed with the SEC and contains forward - looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our b
Slide 3: Investment Highlights
NASDAQ: CNSP 3 INVESTMENT HIGHLIGHTS Developing Anti - Cancer Drug Candidates for the Treatment of Primary and Metastatic Brain and CNS Cancer Lead Program Initially Developed at The University of Texas MD Anderson Cancer Center Lead Program: Berubicin • Optimized anthracycline analog that appears t
Slide 4: Glioblastoma Multiforme (GBM)
NASDAQ: CNSP 4 GLIOBLASTOMA MULTIFORME (GBM) One of the Most Aggressive, Deadly and Treatment - Resistant Cancers That Forms in the Brain 12 – 18 MONTHS Average life expectancy 1 > 50,000 New cases in the 8 Major Markets 2 each year 3 ~ 48% Of all primary malignant brain tumors 1 > 62,000 Forecast o
Slide 5: The Blood Brain Barrier (BBB)
NASDAQ: CNSP 5 THE BLOOD BRAIN BARRIER (BBB) A Tight Layer of Highly Specialized Cells Surrounding the Brain that Prevent Harmful Substances from Penetrating into the Brain • Previously studied anthracyclines have shown no efficacy in brain tumors due to their inability to cross the blood - brain ba
Slide 6: Berubicin for the Treatment of GBM
NASDAQ: CNSP 6 BERUBICIN FOR THE TREATMENT OF GBM First Novel Anthracycline Appears to Cross the Blood - Brain Barrier (BBB) and Concentrates in Tumor Tissue Within the Brain • Anthracyclines have been proven to be among the most effective anti - cancer treatments • Berubicin achieves high brain con
Slide 7: Berubicin: Designed to Cross the BBB and Concentrate in the Tumor
NASDAQ: CNSP 7 BERUBICIN: DESIGNED TO CROSS THE BBB AND CONCENTRATE IN THE TUMOR • Synthetic 4’ - O - Benzylated doxorubicin analog • Topoisomerase II Inhibitor • Highly cytotoxic • Highly lipophilic Berubicin
Slide 8: Phase 1 Study Design
NASDAQ: CNSP 8 PHASE 1 STUDY DESIGN • Thirty - five patients with recurrent or refractory glioblastoma multiforme (GBM) or other primary brain cancers • Berubicin administered intravenously over 2 hours for 3 consecutive days (one course) every 21 days. Doses were escalated using an accelerated titr
Slide 9: Phase 1 Study Results
NASDAQ: CNSP 9 PHASE 1 STUDY RESULTS • 44% of subjects demonstrated “stable disease or better 1 ” • Two partial responses with up to 80% tumor shrinkage • Extremely well tolerated with a good safety profile (no off - target toxicities) • DURABLE COMPLETE RESPONSE (CR) - One subject remains cancer -
Slide 10: Ongoing Potentially Pivotal Trial
NASDAQ: CNSP 10 ONGOING POTENTIALLY PIVOTAL TRIAL • Dose Berubicin 7.1 mg/m2 IV infusion vs. Lomustine 130 mg/m2 oral • Clinical Sites 47 centers across North America and Europe • Primary Endpoint Overall Survival (OS) • Secondary Endpoints Progression Free Survival (PFS); Objective Response Rate (O
Slide 11: Path Towards Potential FDA Approval
NASDAQ: CNSP PATH TOWARDS POTENTIAL FDA APPROVAL • Independent Data Safety Monitoring Board (DSMB) Recommended Continuing Clinical Trial of Berubicin Without Modification • The trial design included a pre - planned, non - binding interim futility analysis. We reached the criteria required by the stu
Slide 12: Multiple Pipeline Expansion Opportunities
NASDAQ: CNSP 12 MULTIPLE PIPELINE EXPANSION OPPORTUNITIES COMMENTS EST. U.S. NEW PATIENTS ANNUALLY PATIENT POPULATION INDICATION Existing data in this population 15,000 Relapsed High Grade Gliomas Primary Brain Tumors High Grade Gliomas are the most common malignant brain tumors in children, and rep
Slide 13: Intellectual Property
NASDAQ: CNSP INTELLECTUAL PROPERTY • Berubicin’s primary protection is currently the Orphan Drug Designation which may enable marketing exclusivity in US market for 7 - years post NDA approval • Additional protection is offered as a New Chemical Entity • CNS is exploring potential additional patent
Slide 14: Management Team
NASDAQ: CNSP MANAGEMENT TEAM Distinctive record of business successes and more than 15 years of experience managing the operations, strategies and finances of public and private companies. PRESIDENT & CHIEF EXECUTIVE OFFICER John M. Climaco , Esq Over 35 years of drug development experience and resp
Slide 15: Board of Directors
NASDAQ: CNSP 15 BOARD OF DIRECTORS Ms. Charles has been a corporate transactions and securities partner at the law firm of Thompson Hine, LLP, since 2010. She c urr ently leads Thompson Hine’s Life Sciences practice and co - heads the securities practice, advising public and emerging biotech and pha
Slide 16: Upcoming Value Driving Milestones
NASDAQ: CNSP UPCOMING VALUE DRIVING MILESTONES Berubicin x Orphan Drug Designation June 2020 x IND Accepted for Berubicin Dec 2020 x Initiated Potentially Pivotal Global Berubicin trial for GBM May 2021 x Fast Track Designation June 2021 x Patient Dosing in Potentially Pivotal Study Expected to Comm
Slide 17: Investment Summary
NASDAQ: CNSP 17 INVESTMENT SUMMARY Developing Anti - Cancer Drug Candidates for the Treatment of Primary and Metastatic Brain and CNS Cancer Lead Program Initially Developed at The University of Texas MD Anderson Cancer Center Lead Program: Berubicin • Optimized anthracycline analog that appears to
Slide 18: Contact Details
Contact Details Investor & Media Relations: JTC Team, LLC Jenene Thomas 833 - 475 - 8247 CNSP@JTCIR.com
Slide 19: Berubicin: Designed to Defeat the Blood Brain Barrier
NASDAQ: CNSP BERUBICIN Designed to Defeat the Blood Brain Barrier 19
CNS Pharmaceuticals — Investor Presentation (April 2024) on 6ix